AsianScientist (Jun. 9, 2016) – The Global Health Innovative Technology Fund (GHIT) has announced ten new funding partnerships that include major global pharmaceutical and biotechnology companies.
The new collaborations include a full funding partnership with FUJIFILM Corporation; an associate partnership with Otsuka Pharmaceutical; affiliate partnerships with GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe Pharma Corporation, Nipro Corporation and Sumitomo Dainippon Pharma; and a sponsorship from Salesforce.com.
Along with GHIT’s existing partners, investments by these ten partners will enable the organization to continue investing in new, innovative technology for neglected diseases, as well as promising candidates that have recently entered clinical trials, or will eventually enter late-stage trials.
“With these new partnerships, in addition to last month’s pledge from the Government of Japan to contribute US$130 million to GHIT’s/UNDP’s replenishment, recent progress has the potential to accelerate these tools even faster into the hands of the doctors, nurses and patients who need them most,” said Dr. Kiyoshi Kurokawa, chair of the board at GHIT.
“We’ll be working with our partners from industry, the Gates Foundation and the Wellcome Trust to realize our full replenishment, and with that, our opportunities to change the face of R&D for global health are boundless.”
Source: Burness; Photo: GHIT.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.